GlassScriptPhysician profile
Linda Davt
NPI 1760945299
$5,385.06
in general payments reported to CMS, 2019-2025
41 companies · $1,549 in 2025
The $1,549 reported for 2025 was more than what 93% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $892 · 2022: $993 · 2023: $959 · 2024: $991 · 2025: $1,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,500.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,992.00 | 2021-2025 | Wegovy |
| Intra-Sana Laboratories | $535.12 | 2022-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Pfizer INC. | $406.70 | 2021-2025 | |
| Exact Sciences Corporation | $324.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $261.20 | 2022-2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $213.05 | 2023-2025 | Watchman Flx, Ams 700, Lux-Dx Insertable Cardiac Monitor |
| Axsome Therapeutics, INC. | $169.04 | 2025 | Symbravo, Auvelity |
| Abbvie INC. | $168.45 | 2021-2024 | |
| Corcept Therapeutics | $143.14 | 2025 | Korlym |
| Daiichi Sankyo INC. | $141.90 | 2021-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $115.45 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.62 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $73.78 | 2023-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $67.25 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $57.85 | 2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.58 | 2024-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $44.80 | 2023-2024 | Freestyle Libre |
| Biohaven Pharmaceutical Holding Company LTD. | $44.24 | 2022 | |
| Intuity Medical INC | $35.54 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Vivus LLC | $32.44 | 2022-2023 | Qsymia |
| Merck Sharp & Dohme LLC | $31.94 | 2021-2023 | Steglatro |
| Currax Pharmaceuticals LLC | $30.75 | 2024 | Contrave |
| Janssen Pharmaceuticals, INC | $29.82 | 2021-2023 | Spravato |
| Asensus Surgical, INC. | $26.51 | 2022 | |
| Dexcom, INC. | $22.88 | 2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $21.03 | 2025 | Inspire |
| Phadia US INC. | $18.32 | 2022 | |
| Invivyd INC | $18.00 | 2025 | Pemgarda |
| Philips North America LLC | $17.78 | 2024 | (Ck7) Extended Holter |
| Astellas Pharma US INC | $17.54 | 2024 | Veozah |
| Kyowa Kirin, INC. | $16.61 | 2023 | Crysvita |
| Scilex Pharmaceuticals INC. | $16.38 | 2025 | |
| Amgen INC. | $15.65 | 2023 | Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $15.44 | 2023 | Gvoke Hypopen |
| Endo Pharmaceuticals INC. | $15.00 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.50 | 2023 | Horizant |
| Takeda Pharmaceuticals U.S.A., INC. | $14.40 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.86 | 2022 | |
| Amarin Pharma, INC. | $12.98 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.52 | 2021 | |
| Echosens North America, INC. | $11.35 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Davt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.